EvoEndo’s system uses a single-use, flexible gastroscope and provides virtual reality entertainment for patients to allow the procedure to be performed without anesthesia or sedation.
Distribution will begin once the companies receive FDA 510(k) clearance, which requires companies to notify the federal agency of its intent to market a product at least 90 days in advance.
